Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 26

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 26
---

and integrity of such information. We also plan to outsource certain elements of our information technology infrastructure; as a result,
we manage independent vendor relationships with third parties who are responsible for maintaining significant elements of our information
technology systems and infrastructure and who may or could have access to our confidential information. The size and complexity of our
information technology systems, and those of our third-party vendors, make such systems potentially vulnerable to service interruptions
and security breaches from inadvertent or intentional actions by our employees, partners or vendors. These systems are also vulnerable
to attacks by malicious third parties and may be susceptible to intentional or accidental physical damage to the infrastructure maintained
by us or by third parties. While we have taken steps to protect such information and have invested in all applicable regulatory requirements
compliance systems to do so, there can be no guarantee that our efforts will prevent service interruptions or security breaches in our
systems or the unauthorized or inadvertent wrongful use or disclosure of confidential information that could adversely affect our business
operations or result in the loss, dissemination or misuse of critical or sensitive information. The increasing sophistication and frequency
of cybersecurity threats, including targeted data breaches, ransomware attacks designed to encrypt our data for ransom and other malicious
cyber activities, pose a significant risk to the integrity and confidentiality of our data systems. A breach our security measures or
the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation or misuse of trade secrets, proprietary information
or other confidential information, whether as a result of theft, hacking, fraud, trickery or other forms of deception, or for any other
cause, could enable others to produce competing products, use our proprietary technology or information, and/or adversely affect our
business position. Further, any such interruption, security breach, loss or disclosure of confidential information could result in financial,
legal, business and reputational harm to us and could have a material adverse effect on our business, financial position, results of
operations and/or cash flow.

<div align='center'>12</div>

Risks Relating to the Development and Commercialization of our Drug Candidates and Regulatory Approval

The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and even if we obtain approval for a product candidate in one country or jurisdiction, we may never obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential.

In order to market and sell our products in the
United States, the European Union and